Nucleic acid for treatment or prevention of immunodeficiency virus infection
View Patent ↗A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.
1. A nucleic acid comprising:
a long terminal repeat (LTR) of human immunodeficiency virus (HIV) with which transcription is induced by Tat protein and/or Rev protein of human immunodeficiency virus; and
a gene comprising the nucleotide sequence set forth in SEQ ID NO: 3 that encodes a naturally occurring E. coli MazF protein, which specifically cleaves a sequence 5′-A/CA-3′ in a single-stranded RNA,
wherein the gene is placed downstream of said LTR so that its expression can be controlled by said LTR; and wherein the gene encoding said MazF protein does not comprise an ACA sequence.
2. A virus vector comprising the nucleic acid of claim 1 .
3. The virus vector of claim 2 , which is a retrovirus vector.